Citadel Advisors
ADCT icon

Citadel Advisors’s ADC Therapeutics ADCT Stock Holding History

Citadel Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,100
Closed -$42.7K – 12871
2025
Q4 		$42.7K Buy
+12,100
New +$49.1K ﹤0.01% 12107
2025
Q3 		– Sell
-38,000
Closed -$102K – 12640
2025
Q2 		$102K Buy
38,000
+33,000
+660% +$69.4K ﹤0.01% 11334
2025
Q1 		$7.05K Sell
5,000
-100
-2% -$170 ﹤0.01% 13712
2024
Q4 		$10.1K Sell
5,100
-3,900
-43% -$10.2K ﹤0.01% 13613
2024
Q3 		$28.4K Sell
9,000
-18,900
-68% -$59.6K ﹤0.01% 12484
2024
Q2 		$88.2K Buy
27,900
+300
+1% +$1.19K ﹤0.01% 11093
2024
Q1 		$124K Buy
+27,600
New +$102K ﹤0.01% 11066
2023
Q4 		– Sell
-2,200
Closed -$1.97K – 14179
2023
Q3 		$1.97K Buy
2,200
+1,900
+633% +$2.53K ﹤0.01% 13779
2023
Q2 		$645 Sell
300
-400
-57% -$899 ﹤0.01% 14070
2023
Q1 		$1.36K Sell
700
-4,800
-87% -$17.7K ﹤0.01% 14316
2022
Q4 		$21.1K Sell
5,500
-5,000
-48% -$20K ﹤0.01% 13102
2022
Q3 		$51K Sell
10,500
-9,400
-47% -$68.1K ﹤0.01% 11607
2022
Q2 		$158K Buy
19,900
+700
+4% +$6.62K ﹤0.01% 10937
2022
Q1 		$282K Sell
19,200
-2,600
-12% -$41.3K ﹤0.01% 10733
2021
Q4 		$440K Buy
+21,800
New +$526K ﹤0.01% 9995
2021
Q3 		– Sell
-15,300
Closed -$373K – 13717
2021
Q2 		$373K Buy
15,300
+4,000
+35% +$92.8K ﹤0.01% 10741
2021
Q1 		$276K Buy
11,300
+4,200
+59% +$122K ﹤0.01% 11035
2020
Q4 		$227K Buy
+7,100
New +$233K ﹤0.01% 9544

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ADCT Position: Q1 2026 in Review

Citadel Advisors increased its ADC Therapeutics (ADCT) stake by 34% in Q1 2026, buying an estimated $400K and bringing the position to 399,721 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #6709.

Citadel Advisors first reported a position in ADCT in Q2 2020 and has held it in 17 quarters since. The position peaked at $7.63M in Q4 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Citadel Advisors held 399,721 shares of ADC Therapeutics worth $1.5M as of Q1 2026.
  • Citadel Advisors bought 101,503 ADC Therapeutics shares in Q1 2026, an estimated $400K.
  • ADC Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6709 holding.
  • Citadel Advisors first reported a position in ADC Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • Citadel Advisors's ADC Therapeutics position peaked at $7.63M in Q4 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.